Molina Healthcare (MOH) continues to garner the attention of hedge funds, likely due to its consistent performance in terms of revenue and enrollment. Last quarter, the healthcare giant exceeded expectations, its Q3 2024 financial results showing increased premiums as one of the main drivers of this growth. Recognizing this strength, Stephens raised Molina Healthcare's price target from $335 to $345, and later, Barclays also lifted the target from $359 to $372. Despite a few adjustments in price targets by other firms, MOH was able to maintain its bullish position due to solid financial reports and a $7.09 million investment from Mediolanum International Funds Ltd. Moreover, Molina Healthcare's strategic growth was particularly highlighted during its Q3 2024 earnings call. It also won a contract in Michigan to provide a new Dual Eligible Benefit Program, contributing to MOH's robust stock performance. Molina's industry outlook is further bolstered by the acquisition of ConnectiCare. Toward the end of 2024, Molina Healthcare demonstrated strategic planning by signing CEO Joe Zubretsky to a new employment agreement and awarding performance-based stock units to the CFO. While the stock hit a 52-week low, it quickly rebounded with a 9% surge on the back of strong Q3 revenue beats.
Molina Healthcare MOH News Analytics from Fri, 09 Feb 2024 08:00:00 GMT to Sat, 26 Oct 2024 16:47:40 GMT -
